Wave life sciences announces closing of upsized public offering of ordinary shares and pre-funded warrants and full exercise of underwriters' option to purchase additional shares

Cambridge, mass., oct. 01, 2024 (globe newswire) -- wave life sciences ltd. (nasdaq: wve), a clinical-stage biotechnology company focused on unlocking the broad potential of rna medicines to transform human health, announced today that it closed its previously announced underwritten public offering, and that the underwriters exercised in full their option to purchase an additional 3,750,000 of its ordinary shares at the public offering price of $8.00 per ordinary share, less underwriting discounts and commissions. after giving effect to the full exercise of the underwriters' option to purchase additional shares, the total number of ordinary shares sold in the offering is 26,875,001 ordinary shares which, along with the sale of pre-funded warrants to purchase 1,875,023 ordinary shares, resulted in aggregate gross proceeds to wave life sciences of approximately $230 million, before deducting underwriting discounts and commissions and offering expenses.
WVE Ratings Summary
WVE Quant Ranking